FierceBiotech3d
GSK, Merck and Pfizer in Ab&B's sights as Chinese vaccine biotech files for IPO
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
FiercePharma12d
JPM25: GSK, Sanofi CEOs welcome 'transparency' in response to anti-vaccine movement in US
The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...
GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
FierceBiotech12d
JPM25, Day 2: Pharma should 'run towards' vaccine efficacy conversations, says GSK CEO
Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...